Pharmaceutical Executive-06-01-2018

Pharmaceutical Executive

Azar and Gottlieb out front in revising rebates, restructuring Medicare, and promoting competition.

Pharmaceutical Executive

Pharm Exec speaks with Joe Wiley, CEO of Amryt Pharma, who is steering a road-less-traveled path for a small pharma-building a sustainable, commercial infrastructure first, with the hopes of accelerating new rare disease drugs to the market.

Pharmaceutical Executive

Weighing the crossover effect of US’s new pricing blueprint. 

Pharmaceutical Executive

Exploring new character benchmarks for today’s pharma executives, and whether they have the transformational traits to lead through change.

Pharmaceutical Executive
From the Editor

June 11, 2018

My first gathering of Pharm Exec's Editorial Advisory Board was both an honor and a learning experience-about us, the industry, and maintaining our mission to the our readers.

Pharmaceutical Executive

Laboratory testing has become a critical access point for sales teams in the age of personalized medicine.

Pharmaceutical Executive

From AI to Alexa, experts in specialty pharma ponder the possibilities for high tech and the patient journey.

Pharmaceutical Executive

There is no magic bullet that will dramatically impact drug pricing to everybody’s liking. But a stepwise approach involving a series of reforms, including taking advantage of the next midterm elections, could point the path toward a solution.

Pharmaceutical Executive

Pharm Exec’s 18th annual listing of the top biopharma players shows that most of the familiar placeholders are holding their ground as they weigh a changing business climate with new opportunities for growth in a potentially resurgent marketplace.

Issue PDF
Pharmaceutical Executive

June 01, 2018

Click the title above to open the Pharmaceutical Executive June 2018 issue in an interactive PDF format.